About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.
Category Archives: FDA Policy
AdComms – Is FDA Getting Less Advice?
As more drugs are being approved, is FDA getting less advice than in the past? FDA maintains a vast network of outside advisors to provide input and counsel to the agency related to decisions on policy as well as product … Continue reading
Posted in Advisory Committee Prepapartion, FDA Image, FDA Policy
Tagged #AdCom, #AdComm, #pharma
Comments Off on AdComms – Is FDA Getting Less Advice?
What They Said – Overview of FDA Press Releases for 2020
Well. They said a lot. A lot more than ever, as one might expect. This past year, FDA issued a whopping 420 press releases, more so by far than any year previously. COVID certainly made a big impact – a … Continue reading
Posted in Current Affairs, FDA Image, FDA Policy
Comments Off on What They Said – Overview of FDA Press Releases for 2020
Approvals in the Crazy Year of 2020
Each year in January, it is relevant to look back on the activities of FDA during the course of the previous year and look at how it was the same or different from prior years, and to look at trends … Continue reading
Posted in Advisory Committee Prepapartion, FDA Image, FDA Policy
Tagged #pharma, Drug Approvals
Comments Off on Approvals in the Crazy Year of 2020
FDA AdComm Agenda Covers the Bases
First of all, we are having a bit of a crisis with our crisis. As we appear to be moving into yet another wave of COVID-19 infections, and as research into a vaccine is aggressively underway, we also see serious … Continue reading
Posted in Advisory Committee Prepapartion, COVID19, Current Affairs, FDA Image, FDA Policy
Tagged #COVID19
Comments Off on FDA AdComm Agenda Covers the Bases
FDA Credibility on the Line
In normal times, when there is no pandemic threatening our lives and livelihoods, it is essential for FDA to maintain the traditional “gold standard” in relation to the decision-making process for the approval of new treatments. That standard is even … Continue reading
Posted in FDA Image, FDA Policy
Tagged #FDA #COVID19 #EUA #BloodPlasma
Comments Off on FDA Credibility on the Line